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The major source of surprise to us is the fact that none
of the many groups who were/are working on the theme
of nephritogenic antigens in acute poststreptococcal
glomerulonephritis (APSGN) have published comparative
studies. Our investigation was an attempt to remedy
this situation.
Before addressing the points raised by Yoshizawa et al.,
we wish to emphasize that there is now agreement on
the data concerning streptococcal zymogen/proteinase
(SPE B) in APSGN. Glomerular deposition of SPE B
has been independently verified,1 and has been confirmed
by Yoshizawa et al. in their APSGN biopsies using anti-
body supplied by us (personal communication). In
addition, a number of independent studies have shown
antibody to SPE B to be an excellent marker of group
A streptococcus infection in general (see Batsford et al.2)
and it is probably the best available serological marker
for APSGN.3
The second streptococcal component studied by us
was glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
known to be identical to plasmin receptor from group
A streptococcus4 and sharing at least 98% homology to
nephritis-associated plasmin receptor, as reported by
Yoshizawa et al.5 themselves. We found glomerular
deposition of GAPDH in 3/17 biopsies and antibody to
GAPDH in 5/47 serum samples from APSGN patients.
These results demonstrate that more than one antigen may
be involved in the pathogenesis of APSGN. The lower
frequency of positive staining for GAPDH, found by us, is
not easily explained by methodology; indirect immuno-
fluorescence is actually more sensitive than direct staining
and has been successfully used to detect glomerular
deposition of many different antigens, as shown in myriad
previous reports. The indirect technique is more likely to
produce false-positive rather than false-negative results.
Minor differences in mobility of fractions in sodium
dodecyl sulfate-polyacrylamide gel electrophoresis re-
ported between laboratories is a common phenomena of
a technical nature, it does not constitute proof of real
differences between antigens. Yoshizawa et al. used a
quantitative immunoblot method to assess serum antibody;
this is not state of the art, it should be confirmed by
enzyme-linked immunosorbent assay testing. If Yoshizawa
et al. are convinced of the existence of isoforms of GAPDH/
plasmin receptor, they should perform complete sequencing
of their antigen preparation, this task is not trivial but with
modern technology it no longer poses great problems.
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To the Editor: We read with surprise the recent paper by
Batsford et al.1 on the nephritogenic antigen for acute
poststreptococcal glomerulonephritis. The authors’ data
regarding glomerular deposition and serum antibody re-
sponse to nephritis-associated plasmin receptor (NAPlr) or
streptococcal glyceraldehyde-3-phosphate dehydrogenase in
acute poststreptococcal glomerulonephritis patients were
completely different from ours.2,3 We detected serum anti-
NAPlr antibody at high titer in 92% (46/50) of acute
poststreptococcal glomerulonephritis patients, and positive
glomerular staining was observed in 100% (25/25) of patients
in the early stage by direct immunofluorescence staining with
rabbit anti-NAPlr antibody.3 We also showed that distribu-
tion of NAPlr deposition and plasmin activity were
identical.4 Discrepancy in histologic staining results is easily
explained by methodology. Batsford et al.1 used the indirect
immunofluorescence staining with the different antibody
that they made, whereas we used direct immunofluorescence
staining for NAPlr because nonspecific staining increases and
specific staining is difficult to assess by indirect methods. We
suspect the discrepancy in serum reactivity against glycer-
aldehyde-3-phosphate dehydrogenase detected by ELISA was
mainly because of the use of different antigens. The antigens
differed in size (37–39 kDa (theirs) vs 43 kDa (ours)). We
suspect the existence of two distinct isoforms of glyceralde-
hyde-3-phosphate dehydrogenase that would show differen-
tial migration by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and different immunologic reactivity.
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